GHRP-6 & GHRP-2
Older GH secretagogues; Real endocrine effect with higher side-effect burden
Brief Overview: GHRP-2 and GHRP-6 are ghrelin-receptor agonists that stimulate growth-hormone release. They can also affect hunger, prolactin, cortisol, glucose, and water retention. Evidence lens: The endocrine mechanism is real, but these compounds are not FDA-approved wellness therapies. They are less selective than ipamorelin and carry anti-doping and compounding concerns. How to read this: if you're new, understand pulse dynamics: the goal is a GH pulse, not a constant drug level. Once you're past the basics, watch for desensitization, glucose changes, prolactin/cortisol spillover, edema, and appetite effects.
- GHRP-2 and GHRP-6 are synthetic growth-hormone-releasing peptides in the older growth-hormone secretagogue family.
- They act at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a.
- GHRP-2 and GHRP-6 are ghrelin/GHS-R agonist secretagogues, not GHRH analogs. They are often grouped, but hunger, cortisol/prolactin spillover, and potency can differ.
- Both compounds trigger pituitary GH release and interact with hypothalamic-pituitary regulation.
- GHRP-6 is more strongly associated with hunger stimulation.
- GHRP-2 is generally described as less appetite-provoking but still less selective than ipamorelin.
- The GH pulse is also shaped by sleep, nutrition, blood glucose, free fatty acids, somatostatin tone, endogenous GHRH, age, adiposity, and prior secretagogue exposure.
- That is why response varies and why repeated stimulation can lose effect.
- They stimulate GH release through GHS-R and work best conceptually when pituitary GH reserve exists. GHRP-6 is more hunger-promoting; GHRP-2 is often described as stronger GH-releasing but less selective than ipamorelin. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Human endocrine studies show that GHRP-6 can stimulate GH secretion and that GHRP-2 can increase food intake and pituitary hormone release.
- Comparative endocrine studies also show that older GHRPs can raise ACTH/cortisol and prolactin more than cleaner secretagogues.
- Pharmacokinetic evidence is limited but useful.
- GHRP-6 has a published human IV PK study in nine healthy men; GHRP-2 has pediatric IV PK/PD data in short-stature children.
- These are not the same as modern wellness-clinic subcutaneous protocols.
- Human endocrine studies show GH release, but body-composition and anti-aging outcomes are not proven at community protocol level. Desensitization/attenuation with repeated exposure is biologically plausible. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: GHRP-2 Acetate [Research/Experimental]; Route: Subcutaneous (SC); Dose: Saturation Dose: 100 mcg; Frequency: 2-3x Daily; Timing: Fasted Rule: no food 2 hours before or 30-60 mins after; Max: 200 mcg (diminishing returns); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: GHRP-6 Acetate [Research/Experimental]; Route: Subcutaneous (SC); Dose: Saturation Dose: 100 mcg; Frequency: 2-3x Daily; Timing: Fasted Rule: no food 2 hours before or 30-60 mins after; Max: 150 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Combined research/anecdotal pattern [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: Typically 100 mcg per injection; Frequency: 2 to 3 times daily; Timing: Empty stomach / avoid elevated blood glucose or fatty acids; Duration: 8 to 12 weeks with rest periods; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Pulse-style use and 5-on/2-off cycles are common, but the exact schedule is not proven necessary. Food timing matters because glucose/fatty acids and somatostatin tone can blunt GH response. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: GHRP-2 about 2 to 3 hours by IV pediatric terminal half-life math; GHRP-6 about 10 to 13 hours by adult IV terminal half-life math.
- Half-life basis: GHRP-2 beta half-life 0.55 +/- 0.14 hours in a small pediatric IV PK/PD study; GHRP-6 distribution half-life 7.6 +/- 1.9 minutes and elimination half-life 2.5 +/- 1.1 hours in nine healthy adult men after IV bolus dosing.
- Beginner translation: The steady-state number is less important here than the GH pulse. These drugs are used for transient signaling; A flat constant exposure is not usually the intended physiology.
- Practical interpretation: Do not copy IV PK numbers directly into subcutaneous self-use assumptions. Route, dose, assay method, and population matter. Monitor IGF-1, fasting glucose, edema, appetite, prolactin/cortisol symptoms, and sleep quality. GHRP-6 may have a longer terminal phase than many community summaries suggest. That does not mean the GH pulse lasts all day; The endocrine response rises and falls much faster than terminal elimination alone implies.
- Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
- Short half-lives support pulse-based interpretation. Short plasma exposure does not eliminate receptor desensitization or downstream IGF-1/glucose issues. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- The classic mechanistic pairing is with a GHRH analog such as CJC-1295 without DAC or sermorelin.
- In that model, the GHRH signal encourages GH synthesis/release readiness and the GHRP signal triggers a release pulse. This is an endocrine concept, not a guarantee of clinical benefit.
- Do not stack multiple GHRPs together just to increase stimulation. Combining GHRP-2, GHRP-6, hexarelin, ipamorelin, or GH itself can amplify edema, glucose disruption, carpal-tunnel-like symptoms, blood-pressure changes, and pituitary-axis noise.
- GHRP-6 may be chosen in research discussions when appetite stimulation is part of the hypothesis; GHRP-2 may be chosen when appetite stimulation is unwanted.
- Often stacked with CJC-1295/no-DAC or sermorelin to combine GHRH and GHS-R signals. Avoid adding multiple GH-axis agents without IGF-1/glucose monitoring. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Expected issues include flushing, hunger, lethargy, water retention, headache, sleepiness, numbness/tingling, glucose changes, and injection-site irritation.
- Prolactin and cortisol elevation are more relevant with older GHRPs than with ipamorelin.
- Avoid in active malignancy, uncontrolled diabetes, untreated sleep apnea, intracranial hypertension risk, pregnancy, and any setting where fluid retention or glucose worsening would be dangerous.
- Watch appetite surges, water retention, tingling, carpal-tunnel symptoms, prolactin/cortisol effects, sleep apnea worsening, and glucose changes. Cancer history and uncontrolled diabetes are important caution contexts. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Useful monitoring includes IGF-1, fasting glucose, HbA1c, fasting insulin if available, blood pressure, edema, weight trend, sleep apnea symptoms, prolactin, cortisol context, and symptom logs.
- A single IGF-1 value does not prove safety or body-composition benefit.
- Track IGF-1, fasting glucose/A1c, weight/waist, edema, blood pressure, sleep apnea symptoms, hunger, and prolactin/cortisol if symptoms suggest spillover. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: not approved; Classified as investigational research chemicals. Both were on the original 19-peptide Category 2 list and are expected to stay there, and neither was among the 12 peptides HHS directed FDA to remove in April 2026.
- Compounding: as of late 2025 many US compounding pharmacies stopped making them under new FDA Bulks List restrictions, shifting practitioners toward ipamorelin or tesamorelin. Access is not expected to return.
- WADA/USADA: banned under S2 and detectable in urine for up to 7 to 10 days after a dose.
- Caveat: commentary cites cortisol and prolactin elevation (especially with GHRP-6) and variable gray-market purity.
- GHRP-2/GHRP-6 are not FDA-approved wellness drugs and may be anti-doping-prohibited. Research-market availability is separate from lawful clinical use. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.